Fluid Compartments & Homeostasis

• Distribution: Water is 50%–60% of adult weight (varies with fat). ICF holds 2/3 of water; ECF holds 1/3 (interstitial fluid/plasma). Weight change is the best fluid shift indicator (1 kg = 1 L).
• Capillary Exchange: Governed by hydrostatic (pushes out) and plasma oncotic (albumin pulls in) pressures. Edema occurs if hydrostatic pressure rises, oncotic falls, or lymphatics are blocked. Third-spacing traps nonfunctional fluid.

Regulatory Mechanisms

• Hormones: Dehydration triggers thirst and pituitary ADH, raising renal water reabsorption. Aldosterone promotes sodium retention and potassium excretion. Atrial stretch releases natriuretic peptides (ANP/BNP) to excrete sodium/water.

Electrolytes & Clinical Imbalances

• Sodium (136–145 mEq/L): Governs ECF osmolality (280–295 mOsm/kg) and impacts CNS. Hypernatremia (>145 mEq/L) causes cell shrinkage; rapid correction risks cerebral edema. Hyponatremia (<136 mEq/L) causes cell swelling; rapid correction risks osmotic demyelination.
• Potassium (3.5–5.0 mEq/L): Dictates membrane potentials. Hyperkalemia (>5.0 mEq/L) causes peaked T waves, wide QRS, and arrest. Treatment: stop intake, diuretics/binders, shift K+ with insulin/beta-agonists, and stabilize heart with IV calcium. Hypokalemia (<3.5 mEq/L) causes flat T waves, U waves, and weakness. IV KCl must be diluted, infused slowly (<10 mEq/hr), and never pushed.
• Divalent Cations: Calcium (9.0–10.5 mg/dL) is regulated by PTH and calcitonin. Hypercalcemia sedates nerves/muscles; hypocalcemia causes tetany with positive Chvostek/Trousseau signs. Magnesium (1.3–2.1 mEq/L) is vital for ATP. Hypomagnesemia (<1.3 mEq/L) resembles hypocalcemia, causing hyperactive reflexes and torsades.

Acid-Base Balance (pH 7.35–7.45)

Regulated by buffers, lung CO2 excretion, and renal bicarbonate/H+ control:

1. Respiratory Acidosis: Carbonic acid excess from hypoventilation (CO2 retention).
2. Respiratory Alkalosis: Carbonic acid deficit from hyperventilation (CO2 depletion).
3. Metabolic Acidosis: Bicarbonate deficit or acid buildup; anion gap is 8–12 mmol/L.
4. Metabolic Alkalosis: Bicarbonate excess or acid loss (vomiting/NG suction).

Crystalloid Solutions

• Tonicity Effects: Hypotonic (e.g., 0.45% NaCl) dilutes ECF, swelling cells to treat hypernatremia. Isotonic (e.g., 0.9% NaCl, Lactated Ringer's) expands ECF volume without shifts. Hypertonic (e.g., 3.0% NaCl) draws water out of cells to treat hyponatremia.

Fluid Compartments & Homeostasis

• Distribution: Water is 50%–60% of adult weight (varies with fat). ICF holds 2/3 of water; ECF holds 1/3 (interstitial fluid/plasma). Weight change is the best fluid shift indicator (1 kg = 1 L).
• Capillary Exchange: Governed by hydrostatic (pushes out) and plasma oncotic (albumin pulls in) pressures. Edema occurs if hydrostatic pressure rises, oncotic falls, or lymphatics are blocked. Third-spacing traps nonfunctional fluid.

Regulatory Mechanisms

• Hormones: Dehydration triggers thirst and pituitary ADH, raising renal water reabsorption. Aldosterone promotes sodium retention and potassium excretion. Atrial stretch releases natriuretic peptides (ANP/BNP) to excrete sodium/water.

Electrolytes & Clinical Imbalances

• Sodium (136–145 mEq/L): Governs ECF osmolality (280–295 mOsm/kg) and impacts CNS. Hypernatremia (>145 mEq/L) causes cell shrinkage; rapid correction risks cerebral edema. Hyponatremia (<136 mEq/L) causes cell swelling; rapid correction risks osmotic demyelination.
• Potassium (3.5–5.0 mEq/L): Dictates membrane potentials. Hyperkalemia (>5.0 mEq/L) causes peaked T waves, wide QRS, and arrest. Treatment: stop intake, diuretics/binders, shift K+ with insulin/beta-agonists, and stabilize heart with IV calcium. Hypokalemia (<3.5 mEq/L) causes flat T waves, U waves, and weakness. IV KCl must be diluted, infused slowly (<10 mEq/hr), and never pushed.
• Divalent Cations: Calcium (9.0–10.5 mg/dL) is regulated by PTH and calcitonin. Hypercalcemia sedates nerves/muscles; hypocalcemia causes tetany with positive Chvostek/Trousseau signs. Magnesium (1.3–2.1 mEq/L) is vital for ATP. Hypomagnesemia (<1.3 mEq/L) resembles hypocalcemia, causing hyperactive reflexes and torsades.

Acid-Base Balance (pH 7.35–7.45)

Regulated by buffers, lung CO2 excretion, and renal bicarbonate/H+ control:

1. Respiratory Acidosis: Carbonic acid excess from hypoventilation (CO2 retention).
2. Respiratory Alkalosis: Carbonic acid deficit from hyperventilation (CO2 depletion).
3. Metabolic Acidosis: Bicarbonate deficit or acid buildup; anion gap is 8–12 mmol/L.
4. Metabolic Alkalosis: Bicarbonate excess or acid loss (vomiting/NG suction).

Crystalloid Solutions

• Tonicity Effects: Hypotonic (e.g., 0.45% NaCl) dilutes ECF, swelling cells to treat hypernatremia. Isotonic (e.g., 0.9% NaCl, Lactated Ringer's) expands ECF volume without shifts. Hypertonic (e.g., 3.0% NaCl) draws water out of cells to treat hyponatremia.

Acute Respiratory Failure (ARF) and Acute Respiratory Distress Syndrome (ARDS) are critical pulmonary conditions where gas exchange is insufficient to support systemic organs1.

The 80/20 Core: Pathophysiology & Clinical Care

1. Classification of ARF ARF is a symptom of inadequate lung function, categorized into two types12:

• Hypoxemic (Oxygenation Failure): $PaO_2 < 60$ mm Hg on room air2. The core defect is inadequate $O_2$exchange, caused by $V/Q$ mismatch, shunt, diffusion impairment, or alveolar hypoventilation23. Shunt is an extreme mismatch where alveoli fill with fluid, making $O_2$ therapy alone ineffective45.
• Hypercapnic (Ventilatory Failure): $PaCO_2 > 50$ mm Hg with $pH < 7.35$6. It represents insufficient $CO_2$ removal6. Primary causes include CNS depression, neuromuscular disease, chest wall abnormalities, or airway obstruction (COPD, severe asthma)7more_horiz.

2. ARDS Pathophysiology & Phases ARDS is a progressive form of ARF triggered by direct or indirect lung injury11more_horiz. Its hallmark is refractory hypoxemia—unresponsive to supplemental oxygen1415. It progresses in three phases16:

• Injury/Exudative (24–72 hours): Inflammatory mediators damage the membrane, causing edema1617. Alveolar type II cells are damaged, reducing surfactant, which causes collapse (atelectasis) and stiff lungs1819.
• Reparative/Proliferative (1–2 weeks): Fibroblasts and inflammatory cells infiltrate, increasing resistance, causing pulmonary hypertension and decreased compliance20.
• Fibrotic/Late Phase: Diffuse scarring and remodeling further reduce gas exchange surface area, correlating with a poor prognosis21.

3. Interprofessional Management Treatment focuses on treating causes, optimizing gas exchange, and avoiding complications122:

• Ventilation Support: BiPAP decreases the work of breathing (WOB) in mild ARF23. Severe ARDS requires low tidal volume ($V_T$) ventilation (4–8 mL/kg) to prevent barotrauma/volutrauma24. This causes permissive hypercapnia (allowing $PaCO_2$ up to 60 mm Hg if $pH \ge 7.30$)2526. High PEEP is applied to recruit collapsed alveoli27.
• Prone Positioning: For severe ARDS with refractory hypoxemia; turning patients prone recruits dorsal alveoli, improving $V/Q$ matching28.
• Supportive Care: Corticosteroids reduce airway inflammation2930. Fluid management keeps patients "on the dry side" to minimize pulmonary edema31. Enteral nutrition should begin within 24–48 hours to preserve respiratory muscle mass32.

Core Concept: Expiratory Airflow Resistance

Obstructive lung diseases—bronchiectasis, cystic fibrosis (CF), asthma, and COPD—share increased expiratory airflow resistance from airway obstruction or narrowing. Drug therapy plays a key role in their clinical management.

1. Bronchiectasis: Mucus Stasis

• Pathophysiology & Presentation: Inflammation destroys elastic and muscular wall structures, causing permanent dilation and impaired mucus clearance. It presents as a persistent cough with thick, purulent sputum. Massive hemoptysis is a life-threatening complication.
• Care: CT scan is the gold standard. Care involves antibiotics (minimum 14 days), bronchodilators, and ACTs with hydration (2-3 L/day).

2. Cystic Fibrosis (CF): Ion Transport Defect

• Pathophysiology & Presentation: An autosomal recessive CFTR mutation disrupts sodium and chloride transport, producing thick, dehydrated mucus that plugs respiratory, GI, and reproductive ducts. This causes progressive organ scarring, pancreatic insufficiency, and malabsorption.
• Care: Sweat chloride testing is the gold standard. Management relies on aggressive ACTs and mucus-liquefying medications (dornase alfa), combined with pancreatic enzyme replacement before meals and mutation-specific CFTR modulators.

3. Asthma: Reversible Airflow Hyperreactivity

• Pathophysiology & Presentation: Inflammation involves mast cells and eosinophils. Triggers cause an early IgE-mediated bronchospasm, often followed by a late-phase response 4-6 hours later. Signs include wheezing, dyspnea, and cough. A sudden absence of wheezing ("silent chest") is an emergency.
• Care: Spirometry confirms reversibility (>12% and >200 mL FEV1 improvement post-bronchodilator). Inhaled corticosteroids (ICS) are first-line anti-inflammatories, often paired with LABAs. SABAs provide rescue relief, and patients follow an Asthma Action Plan based on peak flow zones.

4. COPD: Progressive Airflow Limitation

• Pathophysiology & Presentation: Non-reversible airflow limitation is driven by chronic exposure to toxins, mainly smoking. Inflammation causes alveolar destruction (emphysema), goblet cell hyperplasia, and loss of elastic recoil. It presents with progressive exertional dyspnea, chronic cough, and a "barrel chest".
• Care: Diagnosed when post-bronchodilator FEV1/FVC is <70%. Key care includes smoking cessation and stepwise inhaled drugs (LAMAs, LABAs, ICS). Calorie-dense nutrition combats cachexia, while pursed-lip breathing reduces air trapping.

This summary distills the 20% of core clinical concepts driving 80% of patient outcomes, grounded directly in the provided material.

1. Lower Respiratory Infections: Pneumonia & Tuberculosis (TB)

• Pneumonia: Acute lung parenchymal infection where pathogens invade via aspiration, inhalation, or blood. Inflammation increases vascular permeability, causing capillary leakage and alveolar fluid consolidation, impairing gas exchange. Clinical Rule: Initiate empiric antibiotic therapy immediately upon suspicion to reduce mortality; adjust only after culture results. Prevent aspiration pneumonia by elevating the head of the bed to ≥30° and checking the gag reflexes.
• Tuberculosis (TB): Airborne disease caused by M. tuberculosis. LTBI vs. Active TB: Latent TB (LTBI) is asymptomatic, non-infectious, has normal chest x-rays, and requires single-drug therapy (e.g., isoniazid). Active TB is infectious, symptomatic, and treated with a 4-drug regimen (isoniazid, rifampin, pyrazinamide, ethambutol). Clinical Priority: Due to the rise of multidrug-resistant strains (MDR-TB), Directly Observed Therapy (DOT) is the standard of care for non-adherent patients.

2. Acute Pleural & Trauma Emergencies

• Tension Pneumothorax: A life-threatening emergency where air enters the pleural space on inspiration but cannot escape, causing positive pressure, lung collapse, and mediastinal shift that compresses the heart and unaffected lung. Manifestations: Severe dyspnea, tachycardia, and tracheal deviation. Requires immediate needle decompression and chest tube insertion.
• Flail Chest: Fracture of ≥3 consecutive ribs in ≥2 places, causing paradoxical chest wall movement (moves inward during inspiration, outward during expiration). Treat with oxygen, analgesics, and positive pressure ventilation to stabilize the segment.

3. Vascular & Blockage Emergencies: Pulmonary Embolism (PE)

• Pathophysiology: Blockage of pulmonary arteries by a thrombus (usually from lower-limb DVT), obstructing alveolar perfusion.
• Diagnosis & Management: Dyspnea is the most common symptom. A spiral CT scan is the gold standard for diagnosis (or V/Q scan if contrast is contraindicated). Key Care: Administer immediate anticoagulation (LMWH or IV heparin) to prevent clot extension; long-term therapy (e.g., warfarin) continues for ≥3 months.

4. Oncologic Malignancies: Lung Cancer

• NSCLC vs. SCLC: Non-Small Cell (84%) grows moderately and is treated surgically if diagnosed in early stages (I–IIIA). Small Cell (SCLC, 13%) is highly aggressive, spreads early via blood and lymph (frequently to the brain), and is treated primarily with systemic chemotherapy and prophylactic cranial irradiation.

I. Oxygen Therapy & Delivery Systems

• Target: Maintain SpO2 >92% (or >88% in chronic COPD) or PaO2 >60 mmHg. Supplementing FiO2 >60% for >24 hours risks oxygen toxicity, causing severe pulmonary edema and inflammatory alveolar damage.
• Low-Flow Systems: Nasal Cannula (1–6 L/min, 24%-44% FiO2), Simple Mask (6–12 L/min, 35%-50% FiO2, requires >=6 L/min), Non-Rebreather (10–15 L/min, 60%-90% FiO2, keep reservoir bag inflated).
• High-Flow Systems: Venturi Mask (delivers precise, fixed FiO2 for COPD), High-Flow Nasal Cannula (up to 60 L/min, 100% FiO2, heated humidification).
• CO2 Narcosis: Some COPD patients lose sensitivity to high CO2, relying on a hypoxic drive to breathe. However, never withhold oxygen during severe, life-threatening hypoxemia.

II. Artificial Airways & Ventilation Modes

• Airways: NPA (used in conscious or unconscious patients) vs. OPA (strictly unconscious patients to avoid vomiting/aspiration). Verify ET tube placement immediately via bilateral breath sounds, symmetric chest movement, and EtCO2 capnography; confirm via chest X-ray (2–3 cm above carina).
• Cuff Management: Keep cuff pressure at 20–30 cm H2O to prevent aspiration and protect tracheal capillary perfusion.
• Ventilation Modes:
  • AC (Assist-Control): Preset rate/VT. Spontaneous breaths get full VT; risks hyperventilation and respiratory alkalosis.
  • PC (Pressure Control): Preset pressure; VT varies. Prevents barotrauma in "stiff" or noncompliant lungs.
  • SIMV: Preset rate/VT; spontaneous breaths vary in volume.
  • PSV (Pressure Support): Preset pressure assisting spontaneous breaths; patient controls rate/VT to facilitate weaning.
• PEEP: Splints open alveoli. High PEEP risks decreased venous return, preload, and cardiac output due to increased thoracic pressure.

III. Nursing Interventions & Complications

• Suctioning: Only PRN (not routinely). Hyperoxygenate with 100% FiO2 before/after; limit passes to <10 seconds. Stop insertion when meeting resistance (carina) to avoid mucosal damage.
• VAP Prevention: Elevate HOB 30–45 degrees, perform daily SAT/SBT trials, provide oral care with Chlorhexidine, and initiate early mobility.
• Unplanned Extubation: Stay with the patient, call for help, and manually ventilate with BVM and 100% O2.
• Accidental Decannulation (Trach <7 days): Spread stoma with hemostat, insert tube with obturator, then remove obturator; if impossible, cover stoma and use BVM over mouth/nose.

IV. Chest Tubes & Drainage Systems

• Water-Seal Chamber: Shows tidaling (water rises on inspiration, falls on expiration). Cessation means lung re-expansion or tube occlusion. Continuous bubbling indicates an air leak.
• Disconnection: Submerge the distal end in sterile water to re-establish a water seal. Never routinely clamp or strip chest tubes.

• Gas Exchange: Primary goal: O2/CO2 exchange across alveolar-capillary membrane12.
• Anatomy: Upper tract warms/humidifies/filters air; epiglottis covers larynx to prevent aspiration3. Carina is highly sensitive, triggering vigorous cough on stimulation3.
• Aspiration: Right mainstem bronchus is shorter, wider, straighter than left; aspiration is far more common in right lung4.
• Dead Space: Normal tidal volume ($V_T$) is ~500 mL (~150 mL is anatomical dead space [$V_D$] without gas exchange)2.
• Alveoli & Surfactant: 300M+ alveoli connect via pores of Kohn2. Surfactant lowers surface tension, preventing collapse (atelectasis)2.
• Pleural Biology: Visceral pleura lacks pain fibers5; parietal pleura has pain fibers, causing sharp pleuritic pain during inflammation5.
• Ventilation: Inspiration is active (diaphragm contracts, drawing air in)56; expiration is passive via elastic recoil6.
• Compliance & Resistance: Compliance decreases in edema, ARDS, fibrosis, and increases in COPD6. Resistance is driven by airway diameter7.
• Control: Central chemoreceptors (medulla) respond to CSF pH/$H^+$ changes; peripheral receptors respond to low $PaO_2$, low pH, high $PaCO_2$7. COPD may rely on hypoxic drive7.
• Defense: Alveolar macrophages provide primary defense below bronchioles8. Smoking impairs their phagocytic activity8.

Gerontologic & Assessment Key Concepts

• Aging: Stiffened chest walls, decreased muscle strength, and fewer elastic alveoli cause early airway closure in lung bases (lower $PaO_2$)9. Decreased cilia, cough force, and pharyngeal sensation raise infection/aspiration risks9.
• Hypoxia Findings: Early signs: restlessness, apprehension, tachycardia, mild hypertension, tachypnea10. Late signs: cyanosis, coma, hypotension, accessory muscle use10.
• Physical Exam:
  • Fremitus: High in pneumonia/edema (dense); low in COPD, pleural effusion1112.
  • Percussion: Normal resonance11; hyperresonance in air trapping (COPD, pneumothorax)1112; dullness in fluid/consolidation (effusion, pneumonia)1112.
  • Sounds: Bronchial (trachea, 2:3 ratio), Bronchovesicular (scapulae, 1:1), Vesicular (periphery, 3:1)13.

High-Yield Diagnostics & Procedures

• Oximetry: Arterial $SpO_2$ (normal >95%) is inaccurate if <70%, or with cold, hypoperfusion, vasopressors14. Venous $SvO_2/ScvO_2$ (normal 60-80%) tracks $O_2$ supply/demand balance1415. Low values show anemia, low cardiac output, high demand1516. High values (sepsis) signal poor tissue extraction1516.
• Procedures:
  • Bronchoscopy: Signed consent, NPO 6-12h before, keep NPO after until gag reflex returns17.
  • Thoracentesis: Done sitting upright leaning on table18; post-procedure chest X-ray checks for pneumothorax1718.

This episode explains what "CC Nurse" means in regards to the podcasts and the episodes

Vancomycin (Vancocin) 80/20 Clinical Summary

1. Core Profile & Mechanism

• Class/Action: Glycopeptide bactericidal antibiotic.
• Mechanism: Binds D-alanyl-D-alanine terminus of peptidoglycan precursors. This inhibits cell-wall synthesis (peptidoglycan polymerase and transpeptidation) and alters permeability, leading to cell death. Also inhibits RNA synthesis.
• Spectrum: Gram-positive pathogens only (Staphylococci, Streptococci, Enterococci). Killing is concentration-independent, requiring an AUC/MIC ratio ≥ 400 for efficacy.

2. Therapeutic Uses & Route Dichotomy

• IV Therapy: Septicemia, endocarditis, skin/skin structure, bone/joint, lower respiratory infections, and surgical prophylaxis.
• Oral Therapy: Strictly for C. difficile-associated diarrhea (CDAD) and S. aureus enterocolitis.
• Route Dichotomy: Oral bioavailability is extremely low. Oral doses are excreted in feces and cannot treat systemic infections. Oral is strictly for local GI action; IV is strictly for systemic infections.

3. Administration & Reconstitution

• IV Infusion Rate: Infuse over ≥ 1 hour (10–15 mg/min) to prevent infusion reactions. Loading doses require 2–3 hours.
• Dilution: Reconstituted vials are diluted with compatible fluids (e.g., D5W, 0.9% NaCl) to 5 mg/mL (up to 10 mg/mL for fluid restriction). Higher concentrations increase reaction risk.
• Oral Solutions: Injection vials can be compounded in water/syrup for enteral/nasogastric use.
• Unlabeled Routes: Rectal enemas for CDAD with ileus; preservative-free intrathecal/intraventricular injections for CNS infections.

4. Adverse Effects & Interactions

• Complications: Nephrotoxicity (renal failure), ototoxicity (hearing loss, tinnitus, vertigo), neutropenia, thrombocytopenia, SJS/TEN, DRESS, and anaphylactoid reactions.
• Infusion Reaction: Rapid IV infusion causes histamine release, leading to hypotension, dyspnea, flushing, pruritus, and urticaria. Manage by stopping or slowing the infusion.
• Interactions: Synergistic toxicity with aminoglycosides. Histamine-inducing drugs (ciprofloxacin, opioids, propofol) can hinder desensitization.

5. Monitoring & Interventions (The "20%" Core)

• Therapeutic Drug Monitoring (TDM): Mandatory for IV therapy. Trough levels of 15–20 mg/L target a therapeutic AUC/MIC of 400–600.
• Renal Adjustments: Extend IV intervals in renal impairment based on CrCl or SCr to avoid drug accumulation.
• Key Interventions: Monitor renal function (SCr, BUN), urine output, and auditory symptoms. Assess IV site frequently for phlebitis.

Lanoxin (Digoxin) 80/20 Clinical Summary

1. Expected Action & Mechanism

• Positive Inotrope: Inhibits the Na+/K+-ATPase pump1, raising intracellular sodium. This reverses sodium-calcium exchange to increase intracellular calcium, boosting myocardial contractility, force, and velocity12.
• Negative Chrono/Dromotrope: Increases vagal activity, slowing AV nodal conduction and prolonging refractory period to slow ventricular rate3.

2. Therapeutic Use & Selection

• Indicated for heart failure (HF) and controlling ventricular rate in chronic atrial fibrillation (AF)4. Off-label for fetal supraventricular tachyarrhythmias5.
• Benefit: Boosts cardiac output, lowers sympathetic tone/heart rate, and causes diuresis2. Beta-blockers, verapamil, and diltiazem are replacing it for AF rate control13. Does not convert acute AF to sinus3.

3. Crucial Administration Protocols

• IV: Preferred (IM causes severe pain)67. Dilute 1 mL in $\ge$4 mL sterile water, 0.9% NaCl, or D5W to prevent precipitation8. Inject slowly over $\ge$5 minutes to avoid sudden vasoconstriction8.
• Oral (PO): Tablet bioavailability is 60–80% (solution 70–85%)910. High-fiber meals decrease absorption910.

4. Dosing & Renal Safety Guidance

• Dosing must be based on lean body weight (LBW), efficacy, and serum levels4.
• Geriatric: PIM (avoid first-line); if used, limit to 125 mcg/day to reduce toxicity risk1112.
• Renal GFR Adjustments (Half-life 36–48h)13:
  • >50 mL/min: No adjustment14.
  • 10–50 mL/min: Give 25%–75% of dose every 36h14.
  • <10 mL/min: Give 10%–25% of dose every 48h14.
  • Dialysis: Not removed by dialysis15.

5. Adverse Reactions & Toxicity

• Severe Risks: AV block, bradycardia, VT/VF, cardiac arrest, hyperkalemia, bowel ischemia/necrosis1617.
• Toxicity Signs: Blurred/yellow vision (xanthopsia), GI distress (nausea, vomiting, anorexia), and CNS changes (confusion, delirium, hallucinations)16more_horiz.

6. Priority Nursing Pearls (The 20% to Know)

• Monitoring: Track heart rate (bradycardia risk)16, toxicity, and clinical efficacy4.
• Labs: Monitor GFR/CrCl, potassium (hypokalemia is an adverse reaction; hyperkalemia occurs in toxicity), and digoxin levels16more_horiz.
• Interactions: Digoxin is a P-gp substrate; P-gp inhibitors/inducers trigger drug interactions13. WPW use increases ventricular response risk4.